Details of the Drug

General Information of Drug (ID: DMW7L0Y)

Drug Name

PUL-042

Synonyms

ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agents

Drug Type

Protein/peptide drug

Structure

3D Structure is Not Available

3D MOL is unavailable

2D MOL

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN toll-like receptor 2 (TLR2)	TTAVUMS	TLR2_HUMAN	Agonist	[2]
HUMAN toll-like receptor 6 (TLR6)	TTLSU52	TLR6_HUMAN	Agonist	[2]
HUMAN toll-like receptor 9 (TLR9)	TT2LBCR	TLR9_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04312997) The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection. U.S. National Institutes of Health.
2	Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.